• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 26, 2013

View Archived Issues

Cytokinetics, Astellas: $490M Potential Skeletal Muscle Deal

Cytokinetics Inc.'s deal with Astellas Pharma Inc. to develop skeletal muscle activators for weakness-related disorders preserves rights to tirasemtiv for the biotech firm, and focuses on the follow-on compound, CK-212707 (or CK-107, as it's more often known), providing $40 million for Cytokinetics during the first two years, with potential milestone payments up to $450 million. Read More

Vical, Astellas Begin Phase III Transplant Trial of CMV Vaccine

Vical Inc. and Astellas Pharma Inc. began a Phase III trial of Transvax, a vaccine for cytomeglovirus (CMV), in 500 hematopoietic cell transplant recipients, with Astellas taking the lead and Vical providing development, regulatory and manufacturing support. Read More

BIO, PhRMA Press Forward on PDUFA with Industry Database

Although PDUFA V has been in effect for just nine months, the biopharma industry already is setting up the ironing board for the next round of user fee negotiations with the FDA. Read More

Basilea Shares Rise on $89M BARDA Contract for BAL30072

Shares in Basilea Pharmaceutica AG gained as much as 6 percent during mid-morning trading Tuesday on news that it secured a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), worth up to $89 million, for the development of its antibiotic, BAL30072. Read More

Financings Roundup

• Bluebird Bio Inc., of Cambridge, Mass., closed its initial public offering of about 6.8 million shares at $17 each, which includes the exercise in full by the underwriters of their option to purchase up to 891,176 additional shares. Read More

Other News To Note

• Seattle Genetics Inc., of Bothell, Wash., inked a new antibody-drug conjugate (ADC) oncology collaboration with Bayer HealthCare, a unit of Bayer AG, of Leverkusen, Germany, in exchange for up-front and option exercise fees of up to $20 million, with the prospect of receiving up to $500 million in potential milestones, plus royalties on sales of any products stemming from the multitarget collaboration. Read More

Stock Movers

Read More

Pharma: Other News To Note

• Intas Pharmaceuticals Ltd., of Ahmedabad, India, and its subsidiary, Accord Healthcare Inc., said they entered a settlement and license agreement with Basel, Switzerland-based Roche AG to resolve pending patent litigation related to cancer drug Xeloda (capecitabine). Read More

Pharma: Clinic Roundup

• Boehringer Ingelheim Pharmaceuticals GmbH., of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, disclosed a pooled analysis of Phase III data for the dipeptidyl peptidase-4 inhibitor linagliptin. Read More

Clinic Roundup

• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the Sarah Cannon Research Institute in Nashville opened enrollment in a Phase I study testing MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small-cell lung cancers. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe